Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2010-01, Vol.34 (1), p.e5-e7 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e7 |
|---|---|
| container_issue | 1 |
| container_start_page | e5 |
| container_title | Leukemia research |
| container_volume | 34 |
| creator | Mariani, Stefania Tornaghi, Lucia Sassone, Marianna Basciani, Sabrina Buzzetti, Raffaella Gambacorti-Passerini, Carlo Spera, Giovanni Gnessi, Lucio |
| description | |
| doi_str_mv | 10.1016/j.leukres.2009.08.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734261885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0145212609003919</els_id><sourcerecordid>734261885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-f4d07036f4dff5d6558eca100be01af6e4222f29b155e62faddef5a48dd756783</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EokvhJ4B845RlnMSJcwGhCmilShyAs-XYY9ZbJ15sB5R_j6NdCYlLT3N5783M9wh5zWDPgHXvjnuPy0PEtK8Bhj2IPUDzhOyY6JuKi4Y_JTtgLa9qVndX5EVKRwDgAxuekys29KxnYtgRezep7GY3UhMw0TlkmpYxZTVnp7xf6RSMsyvNB6Q__apxcpqeYrDOI3UzPRU3zjnRPy4fqD7EMBfBtKIPztDtRFUs6iV5ZpVP-Ooyr8mPz5--39xW91-_3N18vK90y4Zc2dZAD01XprXcdJwL1IoBjAhM2Q7buq5tPYyMc-xqq4xBy1UrjOl514vmmrw955YTfy2Yspxc0ui9mjEsSfZNW3dMCF6U_KzUMaQU0cpTdJOKq2QgN8LyKC-E5UZYgpCFcPG9uWxYxgnNP9cFaRF8OAuw_PnbYZRJF0QajYuoszTBPbri_X8J2peKtPIPuGI6hiXOBaJkMtUS5Let5q1lGIq7FNz8BW0UptA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734261885</pqid></control><display><type>article</type><title>Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Mariani, Stefania ; Tornaghi, Lucia ; Sassone, Marianna ; Basciani, Sabrina ; Buzzetti, Raffaella ; Gambacorti-Passerini, Carlo ; Spera, Giovanni ; Gnessi, Lucio</creator><creatorcontrib>Mariani, Stefania ; Tornaghi, Lucia ; Sassone, Marianna ; Basciani, Sabrina ; Buzzetti, Raffaella ; Gambacorti-Passerini, Carlo ; Spera, Giovanni ; Gnessi, Lucio</creatorcontrib><identifier>ISSN: 0145-2126</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2009.08.003</identifier><identifier>PMID: 19717189</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Antineoplastic Agents - therapeutic use ; Benzamides ; Blood Glucose - analysis ; Case-Control Studies ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Female ; Glucose Tolerance Test ; Hematology, Oncology and Palliative Medicine ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Male ; Middle Aged ; Piperazines - therapeutic use ; Pyrimidines - therapeutic use</subject><ispartof>Leukemia research, 2010-01, Vol.34 (1), p.e5-e7</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-f4d07036f4dff5d6558eca100be01af6e4222f29b155e62faddef5a48dd756783</citedby><cites>FETCH-LOGICAL-c419t-f4d07036f4dff5d6558eca100be01af6e4222f29b155e62faddef5a48dd756783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.leukres.2009.08.003$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19717189$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mariani, Stefania</creatorcontrib><creatorcontrib>Tornaghi, Lucia</creatorcontrib><creatorcontrib>Sassone, Marianna</creatorcontrib><creatorcontrib>Basciani, Sabrina</creatorcontrib><creatorcontrib>Buzzetti, Raffaella</creatorcontrib><creatorcontrib>Gambacorti-Passerini, Carlo</creatorcontrib><creatorcontrib>Spera, Giovanni</creatorcontrib><creatorcontrib>Gnessi, Lucio</creatorcontrib><title>Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Blood Glucose - analysis</subject><subject>Case-Control Studies</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Female</subject><subject>Glucose Tolerance Test</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><issn>0145-2126</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv1DAQhS0EokvhJ4B845RlnMSJcwGhCmilShyAs-XYY9ZbJ15sB5R_j6NdCYlLT3N5783M9wh5zWDPgHXvjnuPy0PEtK8Bhj2IPUDzhOyY6JuKi4Y_JTtgLa9qVndX5EVKRwDgAxuekys29KxnYtgRezep7GY3UhMw0TlkmpYxZTVnp7xf6RSMsyvNB6Q__apxcpqeYrDOI3UzPRU3zjnRPy4fqD7EMBfBtKIPztDtRFUs6iV5ZpVP-Ooyr8mPz5--39xW91-_3N18vK90y4Zc2dZAD01XprXcdJwL1IoBjAhM2Q7buq5tPYyMc-xqq4xBy1UrjOl514vmmrw955YTfy2Yspxc0ui9mjEsSfZNW3dMCF6U_KzUMaQU0cpTdJOKq2QgN8LyKC-E5UZYgpCFcPG9uWxYxgnNP9cFaRF8OAuw_PnbYZRJF0QajYuoszTBPbri_X8J2peKtPIPuGI6hiXOBaJkMtUS5Let5q1lGIq7FNz8BW0UptA</recordid><startdate>20100101</startdate><enddate>20100101</enddate><creator>Mariani, Stefania</creator><creator>Tornaghi, Lucia</creator><creator>Sassone, Marianna</creator><creator>Basciani, Sabrina</creator><creator>Buzzetti, Raffaella</creator><creator>Gambacorti-Passerini, Carlo</creator><creator>Spera, Giovanni</creator><creator>Gnessi, Lucio</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100101</creationdate><title>Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia</title><author>Mariani, Stefania ; Tornaghi, Lucia ; Sassone, Marianna ; Basciani, Sabrina ; Buzzetti, Raffaella ; Gambacorti-Passerini, Carlo ; Spera, Giovanni ; Gnessi, Lucio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-f4d07036f4dff5d6558eca100be01af6e4222f29b155e62faddef5a48dd756783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Blood Glucose - analysis</topic><topic>Case-Control Studies</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Female</topic><topic>Glucose Tolerance Test</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mariani, Stefania</creatorcontrib><creatorcontrib>Tornaghi, Lucia</creatorcontrib><creatorcontrib>Sassone, Marianna</creatorcontrib><creatorcontrib>Basciani, Sabrina</creatorcontrib><creatorcontrib>Buzzetti, Raffaella</creatorcontrib><creatorcontrib>Gambacorti-Passerini, Carlo</creatorcontrib><creatorcontrib>Spera, Giovanni</creatorcontrib><creatorcontrib>Gnessi, Lucio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mariani, Stefania</au><au>Tornaghi, Lucia</au><au>Sassone, Marianna</au><au>Basciani, Sabrina</au><au>Buzzetti, Raffaella</au><au>Gambacorti-Passerini, Carlo</au><au>Spera, Giovanni</au><au>Gnessi, Lucio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2010-01-01</date><risdate>2010</risdate><volume>34</volume><issue>1</issue><spage>e5</spage><epage>e7</epage><pages>e5-e7</pages><issn>0145-2126</issn><eissn>1873-5835</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>19717189</pmid><doi>10.1016/j.leukres.2009.08.003</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2010-01, Vol.34 (1), p.e5-e7 |
| issn | 0145-2126 1873-5835 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734261885 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Antineoplastic Agents - therapeutic use Benzamides Blood Glucose - analysis Case-Control Studies Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Female Glucose Tolerance Test Hematology, Oncology and Palliative Medicine Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Middle Aged Piperazines - therapeutic use Pyrimidines - therapeutic use |
| title | Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T16%3A27%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Imatinib%20does%20not%20substantially%20modify%20the%20glycemic%20profile%20in%20patients%20with%20chronic%20myeloid%20leukaemia&rft.jtitle=Leukemia%20research&rft.au=Mariani,%20Stefania&rft.date=2010-01-01&rft.volume=34&rft.issue=1&rft.spage=e5&rft.epage=e7&rft.pages=e5-e7&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2009.08.003&rft_dat=%3Cproquest_cross%3E734261885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734261885&rft_id=info:pmid/19717189&rft_els_id=S0145212609003919&rfr_iscdi=true |